CLAUDIA MEHEDINTU, ELVIRA BRATILA, LACRAMIOARA AURELIA BRINDUSE, MONICA MIHAELA CIRSTOIU, COSTIN BERCEANU, ALINA BORDEA, DIANA ELENA COMANDASU, ANDREEA CARP VELISCU, OVIDIU BRATU, CRISTIAN SAVA, ADRIAN GHEORGHE BUMBU CONTROLED OVARIAN STIMULATION WITH URINARY GONADOTROPHINS AND RECOMBINANT GONADOTROPHINS IN CURRENT PRACTICE The main objective of the this study is to compare the effectiveness of ovarian stimulation with recombinant gonadotrophins (FSHr) versus urinary gonadotrophins (hMG) within the number of oocytes obtained and the number of embryos in the two patient groups, according to age groups and associated pathologies. The study design was retrospective, monocentric. All patients (71) who have addressed the In Vitro Fertilization Clinic of the Prof. Dr. Panait Sirbu Clinical Obstetrics and Gynecology Hospital during 01.01.2010 and 31.12.2010 were included in this research. The total number of oocytes (8.5±3.9 vs 5.7±3.9, p=0.045), the number of fertilized oocytes (7.5±3.6 versus 3.6±2.8 p=0.004) and the number of embryos (6.6±3.5 versus 3.7±2.6, p=0.013) were higher in women under 35 years of age treated with recombinant FSHr compared to women treated with urinary gonadotrophins hMG. Ovarian stimulation with recombinant gonadotrophins provides a greater number of oocytes and a greater number of embryos in all patients, regardless of age and associated pathology. There are many variables that can influence the success rate, but the first variable that can be controlled is the choice of FSHr in daily clinical practice.